Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor

Mikihiro Kawada, Motowo Mizuno, Junichirou Nasu, Tokurou Uesu, Hiroaki Okazaki, Hiroyuki Okada, Hiroyuki Shimomura, Kazuhide Yamamoto, Takao Tsuji, Teizo Fujita, Yasushi Shiratori

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The expression of decay-accelerating factor (DAF), a cell-membrane- complement regulator, is enhanced in colorectal cancer, and DAF is detected in the stools of patients with colorectal cancer. In this study, to elucidate mechanisms whereby DAF is released into the colonic lumen, we analyzed and compared the properties of DAF in stools and colorectal-cancer tissues. Stool specimens taken before surgery and tissue samples from surgically resected colorectal cancers were obtained from 21 patients. We analyzed DAF in stool and tissue specimens using immunoblotting, ultracentrifugation, and phase separation with Triton X-114. We analyzed the expression profile of DAF mRNA in cancer tissues using reverse transcription-polymerase chain reaction to determine whether DAF transcripts for a secretory form of DAF were present. With the use of immunoblotting, stool DAF was detected as a broad band with a molecular weight of around 70,000 kDa that migrated slightly more slowly than cancer-tissue DAF. About 90% of stool DAF was present as a soluble form that remained in the 100,000g supernatant after ultracentrifugation. On phase separation with Triton X-114, the soluble stool DAF was partitioned mainly into the aqueous phase, indicating its hydrophilic nature and lack of the fatty-acid glycosylphosphatidylinositol anchor component. In colorectal cancer tissues, reverse transcription-polymerase chain reaction experiments revealed a nonspliced DAF messenger RNA that encodes a secretory form of DAF in just 2 of the 21 specimens examined. These data suggest that DAF is released from colorectal cancer cells by way of cleavage of membrane-bound DAF at the site of the glycosylphosphatidylinositol anchor.

Original languageEnglish
Pages (from-to)306-312
Number of pages7
JournalJournal of Laboratory and Clinical Medicine
Volume142
Issue number5
DOIs
Publication statusPublished - Nov 2003
Externally publishedYes

Fingerprint

CD55 Antigens
Glycosylphosphatidylinositols
Colorectal Neoplasms
Tissue
Polymerase chain reaction
Ultracentrifugation
Transcription
Immunoblotting
Phase separation
Reverse Transcription
Polymerase Chain Reaction
Messenger RNA

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor. / Kawada, Mikihiro; Mizuno, Motowo; Nasu, Junichirou; Uesu, Tokurou; Okazaki, Hiroaki; Okada, Hiroyuki; Shimomura, Hiroyuki; Yamamoto, Kazuhide; Tsuji, Takao; Fujita, Teizo; Shiratori, Yasushi.

In: Journal of Laboratory and Clinical Medicine, Vol. 142, No. 5, 11.2003, p. 306-312.

Research output: Contribution to journalArticle

Kawada, Mikihiro ; Mizuno, Motowo ; Nasu, Junichirou ; Uesu, Tokurou ; Okazaki, Hiroaki ; Okada, Hiroyuki ; Shimomura, Hiroyuki ; Yamamoto, Kazuhide ; Tsuji, Takao ; Fujita, Teizo ; Shiratori, Yasushi. / Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor. In: Journal of Laboratory and Clinical Medicine. 2003 ; Vol. 142, No. 5. pp. 306-312.
@article{eb4cc1857d2a430d8d530035241fa9be,
title = "Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor",
abstract = "The expression of decay-accelerating factor (DAF), a cell-membrane- complement regulator, is enhanced in colorectal cancer, and DAF is detected in the stools of patients with colorectal cancer. In this study, to elucidate mechanisms whereby DAF is released into the colonic lumen, we analyzed and compared the properties of DAF in stools and colorectal-cancer tissues. Stool specimens taken before surgery and tissue samples from surgically resected colorectal cancers were obtained from 21 patients. We analyzed DAF in stool and tissue specimens using immunoblotting, ultracentrifugation, and phase separation with Triton X-114. We analyzed the expression profile of DAF mRNA in cancer tissues using reverse transcription-polymerase chain reaction to determine whether DAF transcripts for a secretory form of DAF were present. With the use of immunoblotting, stool DAF was detected as a broad band with a molecular weight of around 70,000 kDa that migrated slightly more slowly than cancer-tissue DAF. About 90{\%} of stool DAF was present as a soluble form that remained in the 100,000g supernatant after ultracentrifugation. On phase separation with Triton X-114, the soluble stool DAF was partitioned mainly into the aqueous phase, indicating its hydrophilic nature and lack of the fatty-acid glycosylphosphatidylinositol anchor component. In colorectal cancer tissues, reverse transcription-polymerase chain reaction experiments revealed a nonspliced DAF messenger RNA that encodes a secretory form of DAF in just 2 of the 21 specimens examined. These data suggest that DAF is released from colorectal cancer cells by way of cleavage of membrane-bound DAF at the site of the glycosylphosphatidylinositol anchor.",
author = "Mikihiro Kawada and Motowo Mizuno and Junichirou Nasu and Tokurou Uesu and Hiroaki Okazaki and Hiroyuki Okada and Hiroyuki Shimomura and Kazuhide Yamamoto and Takao Tsuji and Teizo Fujita and Yasushi Shiratori",
year = "2003",
month = "11",
doi = "10.1016/S0022-2143(03)00137-9",
language = "English",
volume = "142",
pages = "306--312",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor

AU - Kawada, Mikihiro

AU - Mizuno, Motowo

AU - Nasu, Junichirou

AU - Uesu, Tokurou

AU - Okazaki, Hiroaki

AU - Okada, Hiroyuki

AU - Shimomura, Hiroyuki

AU - Yamamoto, Kazuhide

AU - Tsuji, Takao

AU - Fujita, Teizo

AU - Shiratori, Yasushi

PY - 2003/11

Y1 - 2003/11

N2 - The expression of decay-accelerating factor (DAF), a cell-membrane- complement regulator, is enhanced in colorectal cancer, and DAF is detected in the stools of patients with colorectal cancer. In this study, to elucidate mechanisms whereby DAF is released into the colonic lumen, we analyzed and compared the properties of DAF in stools and colorectal-cancer tissues. Stool specimens taken before surgery and tissue samples from surgically resected colorectal cancers were obtained from 21 patients. We analyzed DAF in stool and tissue specimens using immunoblotting, ultracentrifugation, and phase separation with Triton X-114. We analyzed the expression profile of DAF mRNA in cancer tissues using reverse transcription-polymerase chain reaction to determine whether DAF transcripts for a secretory form of DAF were present. With the use of immunoblotting, stool DAF was detected as a broad band with a molecular weight of around 70,000 kDa that migrated slightly more slowly than cancer-tissue DAF. About 90% of stool DAF was present as a soluble form that remained in the 100,000g supernatant after ultracentrifugation. On phase separation with Triton X-114, the soluble stool DAF was partitioned mainly into the aqueous phase, indicating its hydrophilic nature and lack of the fatty-acid glycosylphosphatidylinositol anchor component. In colorectal cancer tissues, reverse transcription-polymerase chain reaction experiments revealed a nonspliced DAF messenger RNA that encodes a secretory form of DAF in just 2 of the 21 specimens examined. These data suggest that DAF is released from colorectal cancer cells by way of cleavage of membrane-bound DAF at the site of the glycosylphosphatidylinositol anchor.

AB - The expression of decay-accelerating factor (DAF), a cell-membrane- complement regulator, is enhanced in colorectal cancer, and DAF is detected in the stools of patients with colorectal cancer. In this study, to elucidate mechanisms whereby DAF is released into the colonic lumen, we analyzed and compared the properties of DAF in stools and colorectal-cancer tissues. Stool specimens taken before surgery and tissue samples from surgically resected colorectal cancers were obtained from 21 patients. We analyzed DAF in stool and tissue specimens using immunoblotting, ultracentrifugation, and phase separation with Triton X-114. We analyzed the expression profile of DAF mRNA in cancer tissues using reverse transcription-polymerase chain reaction to determine whether DAF transcripts for a secretory form of DAF were present. With the use of immunoblotting, stool DAF was detected as a broad band with a molecular weight of around 70,000 kDa that migrated slightly more slowly than cancer-tissue DAF. About 90% of stool DAF was present as a soluble form that remained in the 100,000g supernatant after ultracentrifugation. On phase separation with Triton X-114, the soluble stool DAF was partitioned mainly into the aqueous phase, indicating its hydrophilic nature and lack of the fatty-acid glycosylphosphatidylinositol anchor component. In colorectal cancer tissues, reverse transcription-polymerase chain reaction experiments revealed a nonspliced DAF messenger RNA that encodes a secretory form of DAF in just 2 of the 21 specimens examined. These data suggest that DAF is released from colorectal cancer cells by way of cleavage of membrane-bound DAF at the site of the glycosylphosphatidylinositol anchor.

UR - http://www.scopus.com/inward/record.url?scp=0345255808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345255808&partnerID=8YFLogxK

U2 - 10.1016/S0022-2143(03)00137-9

DO - 10.1016/S0022-2143(03)00137-9

M3 - Article

C2 - 14647034

AN - SCOPUS:0345255808

VL - 142

SP - 306

EP - 312

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 5

ER -